Products and offerings.

The company has a wide range of products with more than 150 API and 1600 formulations.

No single product contributes to more than 2% of sales.

Some of the major Product are Vanlid 150,VC15,Enta Vir 150.

Market Share and ReachLargest Market share of 5.3% in Indian retail

Pharma sales.20 products in top 200 Pharma brands in India. Market leader in respiratory and Anti-Viral

categories.Distribution network of 42 sales depots,2300

stockist, 160000 chemists and over 4800 sales personnel.

Location of plants and FactoriesPlants all over India in locations like Himachal

Pradesh, Bangalore, Maharashtra, Goa, Madhya Pradesh.

Company plans to spend around 19Bn Rs over the next few years to modernize and build new plants

Most of the plants have UD FDA approval.The absence of plants near ports can increase the

logistical costs when it comes to exports.

Business ModelCipla has low risk Business model where it partners

with foreign pharma companies to distribute its APIs. It has partnership with companies in 170 countries and

has 7000 product registrations.Exports contribute to more than 50% of sales with

Africa contributing to 36% of exports.The RnD expense has increased steadily by 17% YoY

enabling CIPLA to gain more patents.